E
EvlaBio
We are a Swiss biotech company focused on the development of drug programs with significant unmet medical needs
About EvlaBio
EvlaBio is a Swiss-German life science company established in 2022, concentrating on the development of treatments for the cardiorenal sector. The company's primary focus is on creating a therapy for Left Ventricular Hypertrophy (LVH) in individuals with Chronic Kidney Disease (CKD), a condition with few effective treatment options. EvlaBio's main product is a first-in-class monoclonal antibody designed to inhibit the pathological FGF23/FGFR4 cardiac signaling axis, which is a key factor in the cardiac remodeling seen in CKD patients. This therapeutic approach is intended to directly target a key pathway at the cardiomyocyte level, offering a way to modify the disease's progression at its source.
The company's scientific foundation originates from the Lead Discovery Center GmbH (LDC), an entity established by the Max Planck Innovation technology transfer organization. The program was developed in partnership with the KHAN Technology Transfer Fund I GmbH & Co KG. EvlaBio was co-founded by CEO Wenzel von der Heydte and COO Thomas Kirmeier. In July 2025, EvlaBio secured €21 million in a significant seed funding round to advance its lead program through preclinical development and toward IND-enabling studies. This financing was led by a consortium of investors including Kurma Partners, AdBio Partners, Boehringer Ingelheim Venture Fund, NRW.Venture (NRW.BANK), and HTGF.
The business model is centered on the research, development, and eventual commercialization of its monoclonal antibody. This involves navigating the rigorous, multi-phase process of clinical trials to demonstrate safety and efficacy before seeking regulatory approval for market entry. The company serves patients with CKD and associated cardiac complications, a market segment with a substantial unmet medical need. Successful development could lead to licensing agreements with larger pharmaceutical firms or direct commercialization, generating revenue through the sale of the approved therapy to healthcare systems and providers globally.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Zurich, Switzerland
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 87.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Jul 2025 | $23M | $92M | HTGF · AdBio partners · Boehringer Ingelheim Venture Fund · NRW Venture | ↗ |
Growth signals
Latest recorded traffic for EvlaBio is 1.2K monthly website visits, up 650% over the last three months. EvlaBio's team grew 133.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Kurma Partners
HTGF
AdBio partners
Boehringer Ingelheim Venture Fund
NRW Venture
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about EvlaBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EvlaBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.